Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Binocular Vision Suppression Clear all
Completed Phase 1 Interventional

Spreading Depolarization and Ketamine Suppression

NCT02501941
View directory record Official record
Conditions
Cortical Spreading Depolarization, Cortical Spreading Depression, Subarachoid Hemorrhage, Traumatic Brain Injury
Interventions
ketamine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Micropulse for Suppression of Diabetic Macular Edema

NCT03519581
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Micropulse Laser Treatment, Sham Treatment
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Results available

Hematopoietic Stem Cell Support in Vasculitis

NCT00278512
View directory record Official record
Conditions
Vasculitis
Interventions
Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant, Cyclophosphamide, ATG (rabbit), G-CSF, Campath-1h, Fludarabine, Tacrolimus, Mesna
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000975
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen

NCT00200369
View directory record Official record
Conditions
HIV Infection
Interventions
MEMS cap
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2009 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

NCT04225988
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Extended-release tacrolimus, Immediate-release tacrolimus
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline

NCT03968562
View directory record Official record
Conditions
Hives
Interventions
2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

NCT06235697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Radiation SBRT only, ADT
Radiation · Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
46
States / cities
Antioch, California • Dublin, California • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough

NCT06960759
View directory record Official record
Conditions
Chronic Cough (CC), Refractory Chronic Cough, Unexplained Chronic Cough
Interventions
BCS+inactive, BCS+active
Behavioral · Combination Product
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 99 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

NCT03739996
View directory record Official record
Conditions
HIV Infections
Interventions
Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, Standard of Care (SOC) ART
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)

NCT01477762
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

The CRISIS Prevention Study

NCT00395161
View directory record Official record
Conditions
Sepsis
Interventions
Metoclopramide, Zinc, Glutamine, Selenium, saline, sterile water, selenium, whey-protein
Drug · Dietary Supplement · Other
Lead sponsor
Michael Dean
Other
Eligibility
12 Months to 17 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

NCT07215468
View directory record Official record
Conditions
HIV -1 Infection
Interventions
TMB-365, TMB-380, Baseline ART
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Burst Suppression Anesthesia for Treatment of Severe Depression

NCT02935647
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Diprivan
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Beef-Forward Ready-to-Eat Meals on Recovery Following Simulated Fire Suppression Activities

NCT07822048
View directory record Official record
Conditions
Physical Performance Parameters, Exercise Recovery, Cognition, Muscle Damage, Blood Biomarkers, Stress
Interventions
Beef-Based Protein Ready-to-Eat Meals, Plant-Based Protein Ready-to-Eat Meals
Other
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Fort Worth, Texas • Huntsville, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression

NCT00903448
View directory record Official record
Conditions
Healthy
Interventions
Prilosec OTC (omeprazole-magnesium), Prevacid
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Bulimia Nervosa: A Biobehavioral Study (The Eating Disorder Study)

NCT01830374
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Not listed
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

NCT02991898
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Undifferentiated Leukemia
Interventions
Infusion of Treg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV

NCT06375135
View directory record Official record
Conditions
ART Adherence
Interventions
TXTXT, e-Navigation, Ecological Momentary Assessment (EMA) supported e-Navigation.
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational

ET Stigma Response to Tremor Suppression

NCT07430761
View directory record Official record
Conditions
Action Tremor, Stigma, Social
Interventions
stereotactic thalamotomy with focused ultrasound
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Circadian OS Technology on Melatonin Suppression

NCT07095270
View directory record Official record
Conditions
Circadian Disruption
Interventions
Circadian OS software
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
30 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

NCT00706966
View directory record Official record
Conditions
Nonmalignant Neoplasm, Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 17, 2026, 5:15 AM EDT